This document aims to provide interim guidance for microbiology and virology experts, other laboratory professionals, laboratory managers, infectious disease programme managers, public health professionals and other stakeholders that provide primary, confirmatory or advanced testing for SARS-CoV-2, ...including genomic sequencing, or are involved in making decisions on establishing or scaling up capability and capacity to detect and characterize circulating SARS-CoV-2 variants.
more
Apresentação do PLANO NACIONAL DE EXPANSÃO DA TESTAGEM PARA COVID-19 e orientações acerca dos dois
The COVID-19 CARE pathway is a living tool to support health care workers visualize the current clinical and therapeutic recommendations to be considered in the care planning for patients with COVID-19.
The COVID-19 CARE pathway is aligned with the eighth version of the WHO Therapeutics and COVID...-19: living guideline published on the 14 January 2022 and the third version of the WHO COVID-19 Clinical management: living guidance published on the 23 November 2021.
more
Available in Arabic, Chinese, English, French, Portuguese, Russian and Spanish
https://apps.who.int/iris/handle/10665/334254
By end of March 2022:
42 COVID-19 detection laboratories were assessed in the 1st Quarter 2022.
23 (55%) Labs are reported fully functional, while 19 (45%) requires assistance to fully operate (i.e., medical supplies, equipment, maintenance, and staffing).
34 (89%) labs have RT-...PCR machines, while 4 (11%) doesn’t have.
Most laboratories operate 1 shift of 8 hours 13 (34%), followed by 2 shifts of 16 hours 11 (29%).
Over 1000 testing capacity per day is reported in Tripoli Biotechnical Centre Lab (5,000), Azzawya NCDC Lab (2,500), Tripoli NCDC public health lab (1500), Misrata NCDC Lab (1,300), and Misrata Medical centre Lab (1,300).
The reported needs ranked per priority are equipment, consumables, and staff training; consequently.
more
Available in Arabic, Chinese, English, French, Portuguese and Spanish
https://apps.who.int/iris/handle/10665/334254
Communicable Disease Control Branch
Communicable Disease Management Protocol – Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), February 2010
End TB.
Accessed in November 2017.
Based on communication with the Ukrainian Ministry of Health WHO will continuously revise and publish a list of critical needs against which we are requesting support
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0
Parasites & Vectors volume 15, Article number: 389 (2022)
Dengue is one of the common arboviral infections and is a public health problem in South East Asia. The aim of this systematic review and meta-analysis was to evaluate the prevalence and distribution of dengue in SAARC (South Asian Associ...ation for Regional Cooperation) countries.
more
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more